Newron Pharmaceuticals SpA Email Format

Biotechnology ResearchLombardy, Italy11-50 Employees

Newron Pharmaceuticals SpA is a biotechnology company focused on developing therapies for diseases of the central and peripheral nervous system. Its lead candidate, evenamide, is a first-in-class glutamate modulator with potential as an add-on treatment for treatment-resistant schizophrenia and for patients who respond poorly to standard therapies. Evenamide is active in a global Phase III program for treatment-resistant schizophrenia, with the ENIGMA-TRS 2 trial launched in the United States. The company is headquartered in Bresso, near Milan, Italy, and operates with a relatively small workforce. It has development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other parts of Asia, and with Myung In Pharm for South Korea; its marketed product Xadago/safinamide has approvals in multiple regions and is commercialized through partners such as Zambon, with U.S. rights held by Supernus and Meiji Seika responsible for development and commercialization in Japan and other key Asian markets.

Get verified Newron Pharmaceuticals SpA emails free

Company overview Employee directory